Indexed by Science Citation Index (SciSearch), International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate

ISSN: 1596-5996 (print); 1596-9827 (electronic)-


Home | Back Issues | Current Issue | Review manuscript | Submit manuscript

 
 

This Article

 

Abstract

 

Full-Text (PDF)

 

Table of contents

 

Comments

 

Letters

 

Comments to Editor

 

e-mail Alert

 

Sign Up

 

Original Research Article


 

Metabolites from Actinomyces Strain H6552 Extract Inhibit Transforming Growth Factor-Mediated Pulmonary Fibrosis

 

Rhun Yian Koh1,2, Chooi Ling Lim1,2, Coy Choke Ho3, Bruce David Uhal4, Maha Abdullah1, Sharmili Vidyadaran1 and Heng Fong Seow1*

1Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, 2Department of Human Biology, School of Medicine, International Medical University, No. 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000 Kuala Lumpur, 3Biotechnology Programme, School of Science and Technology, University Malaysia Sabah, Locked Bag 2073, 88999 Kota Kinabalu, Sabah, Malaysia, 4Department of Physiology and Biomedical Sciences, Michigan State University, 2201 Biomedical Physical Sciences, East Lansing, MI 48837, USA

 

*For correspondence: Email: shf@upm.edu.my; Tel: 603-8947 2387; Fax: 603-8946 4232

 

Received: 25 February 2014                                                                  Revised accepted: 13 September 2014

 

Tropical Journal of Pharmaceutical Research, November 2014; 13(11): 1815-1823

http://dx.doi.org/10.4314/tjpr.v13i11.7   

Abstract

 

Purpose: To evaluate the effects of H6552 extract in inhibiting transforming growth factor (TGF)-mediated pulmonary fibrosis in vitro and in vivo.

Methods: Maximum-nontoxic dose (MNTD) of Actinomyces H6552 extract was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphhenyltetrazolium bromide (MTT) assay. Effect of the extract on IMR-90 lung fibroblasts proliferation was determined by calculating the population doubling time (PDT). Collagen gel contraction assay was carried out to determine cell contractility while α-smooth muscle actin (SMA) level in cells was evaluated by quantitative real-time polymerase chain reaction (PCR) and immunostaining methods. A bleomycin-induced ICR mouse model was used in the study to determine the effect of the extract in vivo. The animals received treatments in two regimes: early treatment in which treatment was given on Day 0 and delayed treatment with treatment on Days 5 and 10. The animals were sacrificed on Day 14 and the lungs removed for histopathological assessment.

Results: The MNTD of the H6552 extract was 1625 ± 459.62 μg/ml. H6552 extract significantly reduced TGF- β-mediated cell proliferation, gel contraction and α-SMA expression. PDT was increased up to 83.84 % in the treated cells. Gel contraction was inhibited by the addition of 1000 μg/ml of H6552 extract. Immunostaining results revealed negligible α-SMA antibody staining after H6552 extract treatment at 500 μg/ml. The extract also inhibited lung injury (54 % reduction in Ashcroft score) when early treatment was provided. Delayed treatment with the extract did not show any significant changes in the animals.      

Conclusion:  H6552 extract inhibited TGF-β-induced pulmonary fibrosis and elucidation of its bioactive metabolites may yield a potential agent to treat the disease.

 

Keywords: Actinomyces H6552, Transforming growth factor-β, Cell contractility, α-Smooth muscle actin, Pulmonary fibrosis

Copyright@2002-2010. Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City. All rights reserved.

Powered by Poracom E-mail: jmanager@poracom.net